We are a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets we serve through the development, manufacture and marketing of a broad range of solid, liquid and injectable generic and in-licensed pharmaceutical products.
- 11-Jan-2010
- » Hikma announces partnership with BioCryst for its pandemic flu product
- London, 11 January 2009: Hikma Pharmaceuticals PLC (“Hikma”) (LSE:HIK) (NASDAQ Dubai: HIK), a leading speciality pharmaceutical company, announces that it has signed an exclusive agreement to represent BioCryst in respect of its anti-viral product peramivir for pandemic flu treatment stockpiling opportunities with governments in the Middle East and North Africa (‘MENA’) region.
- 06-Jan-2010
- » Hikma to present at the 2010 J.P. Morgan Healthcare Conference
- Said Darwazah, Hikma’s Chief Executive Officer, will present at the 28th Annual J.P. Morgan Healthcare Conference, on Thursday, January 14, 2010, at 8:00 a.m. Pacific Time, 11:00 a.m. Eastern Time and 4:00 p.m. GMT.
